The Influence of Estradiol/follicle and Estradiol/oocyte Ratios on the Outcome of Controlled Ovarian Stimulation for in Vitro Fertilization
Overview
Gynecology & Obstetrics
Authors
Affiliations
Objective: The aim of the study was to evaluate the influence of the ratios of estradiol (E2) to either the number of follicles >14 mm on the day of human chorionic gonadotropin administration (E2/follicle) or the number of oocytes retrieved (E2/oocytes) during controlled ovarian hyperstimulation (COH) with gonadotropin-releasing hormone (GnRH)-agonist (agonist group) and GnRH-antagonist (antagonist group), on the outcome of in vitro fertilization (IVF) cycles.
Patients And Methods: All consecutive women aged <35 years admitted to our IVF unit during a 6-year period with normal to high response to COH were retrospectively studied. Ovarian stimulation characteristics, number of oocytes retrieved, number of embryos transferred and pregnancy rate were assessed.
Results: Six hundred and ninety consecutive IVF cycles were evaluated, 301 in the agonist group and 389 in the antagonist group. The ratios of E2/follicle and E2/oocyte were significantly higher in the agonist group (p < 0.001 for both). Moreover, while pregnancy rates within E2/oocyte ratio of 100-200 pg/ml were comparable between the agonist and antagonist groups, when E2/oocyte ratios were <100 pg/ml or >200 pg/ml, pregnancy rates were significantly higher in the agonist group. Furthermore, no difference in pregnancy rates was observed within the agonist group between different E2/oocytes ratios, while within the antagonist group, higher pregnancy rates were observed when comparing those with E2/oocyte ratio of 100-200 pg/ml with those with E2/oocyte ratio <100 pg/ml or >200 pg/ml.
Conclusion: While E2/oocyte ratio cannot predict the success of GnRH-agonist protocol, patients undergoing GnRH-antagonist protocol should reach E2/oocyte ratio within the 100-200 pg/ml range in order to achieve the best IVF outcome.
More is not always better-lower estradiol to mature oocyte ratio improved IVF outcomes.
Aslih N, Michaeli M, Mashenko D, Ellenbogen A, Lebovitz O, Atzmon Y Endocr Connect. 2021; 10(2):146-153.
PMID: 33416511 PMC: 7983485. DOI: 10.1530/EC-20-0435.
Merviel P, Menard M, Cabry R, Scheffler F, Lourdel E, Le Martelot M Reprod Sci. 2020; 28(2):495-509.
PMID: 32886340 DOI: 10.1007/s43032-020-00307-2.
Taheri F, Omidi M, Khalili M, Agha-Rahimi A, Sabour M, Faramarzi A J Reprod Infertil. 2020; 21(1):11-16.
PMID: 32175261 PMC: 7048692.
Haas J, Bassil R, Gonen N, Meriano J, Jurisicova A, Casper R Reprod Biol Endocrinol. 2018; 16(1):54.
PMID: 29843716 PMC: 5975523. DOI: 10.1186/s12958-018-0367-5.
Palmerola K, Rudick B, Lobo R J Assist Reprod Genet. 2018; 35(9):1675-1682.
PMID: 29704227 PMC: 6133823. DOI: 10.1007/s10815-018-1192-7.